Journals / Türk Kardiyoloji Derneği Arşivi / 2001 / Cilt: 29 - Sayı: 2

Coronary sinus endothelin-1 levels in patients with PTCA and stent implantation

Koroner anjiyoplasti ve stent uygulanan hastalarda koroner sinüste endotelin-1 düzeyleri

Pages
93–99
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In both the PTCA and stent groups significant ET-1 increases were detected after the procedure (1.64 ± 0.15 vs 3.28 ± 0.39 pg/ml, p < 0.0001; 1.28 ± 0.13 vs 2.72 ± 0.24 pg/ml, p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Endothelin-1 (ET-1) is a vasoactive peptide originating from the endothelium and has mitogenic properties.
📊
Key Findings & Data:In this study, the effect of the PTCA and stent implantation on ET-1 release in the coronary artery was investigated.
💡
Conclusion & Impact:In both the PTCA and stent groups significant ET-1 increases were detected after the procedure (1.64 ± 0.15 vs 3.28 ± 0.39 pg/ml, p < 0.0001; 1.28 ± 0.13 vs 2.72 ± 0.24 pg/ml, p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Endothelin-1 (ET-1) is a vasoactive peptide originating from the endothelium and has mitogenic properties. It is the strongest vasoconstrictor substance, and its activation by atherosclerosis contributes to the progression of this process. It was shown that some physical factors such as mechanical pressure and stretch to the vessel wall causes endothelin release. In this study, the effect of the PTCA and stent implantation on ET-1 release in the coronary artery was investigated. For this purpose, 41 patients who had stable angina pectoris and were candidates for elective PTCA and stent implantation were divided into 2 groups: patients in whom only PTCA (group I, n=22) and patients in whom stent implantation was additionally (group II, n=19) performed. Just before the procedure and 15 minutes after the last balloon inflation, blood samples were taken from coronary sinus for ET-1 measurements. In both the PTCA and stent groups significant ET-1 increases were detected after the procedure (1.64 ± 0.15 vs 3.28 ± 0.39 pg/ml, p < 0.0001; 1.28 ± 0.13 vs 2.72 ± 0.24 pg/ml, p

Özet

Endotel kaynaklı, mitojenik özelliklere sahip vazoaktif bir peptid olan Endotelin-1 (ET-1) günümüzde bilinen en güçlü vazokonstriktör maddedir. ET-1'in ateroskleroziste aktive olduğu ve sürecin ilerlemesine katkıda bulunduğu bilinmektedir. İn vitro çalışmalarda, damar duvarına mekanik basınç ve gerilme gibi fiziksel faktörlerin ET-1 salınmasına neden olduğu gösterilmiştir. Bu çalışmada, koroner anjiyoplasti (PTCA) ve stent işleminin koroner arter ET-1 salınımına etkisi araştırılmıştır. Bu amaçla elektif PTCA ve/veya stent kararı verilen, stabil anjina pektorisli 41 hasta, sadece PTCA yapılanlar (n=22) ve stent yerleştirilenler (n =19) olarak iki gruba ayrıldı. İşlemlerden hemen önce ve son balon şişirilmesinden 15 dakika sonra koroner sinüsten ET-1 ölçümleri için kan alındı. Gerek PTCA, gerekse stent grubunda işlem sonrası ET-1'de bazal değerlere göre anlamlı artışlar saptandı. (sırasıyla; 1.64 ± 0.15 - 3.28 ± 0.39 pg/ml, p < 0.0001 ve 1.28 ± 0.13 - 2.72 ± 0.24 pg/ml, p

🔖

Cite This Article

UÇAR, R., YEŞİLDAĞ, O., SAĞKAN, O., ŞAHİN, M., BAHADIR, H. (2022). Coronary sinus endothelin-1 levels in patients with PTCA and stent implantation. Türk Kardiyoloji Derneği Arşivi, Cilt: 29 - Sayı: 2, 93–99. https://ajindex.com/articles/634045

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Duncan WJ, Bharadwaj B, Tyrrell MJ: Mitral valve replacement in the neonate: a report of two cases. Pediatr Cardiol 1984;5:307-12
  2. Uva MS, Galletti L, Gayet FL, Piot D, Serraf A, Bruniaux J, Conas J, Roussin R, Touchot A, Binet JP: Surgery for congenital mitral valve disease in the first year of life. J Thorac Cardiovasc Surg 1995;109:163-76
  3. Moore P, Adatia I, Spevak PJ, Keane JF, Perry SB, Castenada AR, Lock JE: Severe congenital mitral stenosis in infants. Circulation 1994;89:2099-106
  4. Chen GY, Tseng CD, Chiang FT, Hsu KL, Lo HM, Tseng YZ, Lin FY: Congenital mitral stenosis: challenge of percutaneous transvenous mitral commissurotomy. Int J Cardiol 1997;60:99-102
  5. Ino T, Shimazaki S, Iwahara M, Miyazaki E, Yabuta K, Inoue K: Successful balloon mitral commissurotomy in a small child: use of small Inoue balloon catheter. Ann Thorac Surg 1993;56:168-70
  6. Spevak PJ, Bass JL, Ben-Shachar G, Hesslein P, Keane JF, Perry S, Pyles L, Lock JE: Balloon angioplasty for congenital mitral stenosis. Am J Cardiol 1990;66:472-6
  7. Kadoba K, Jonas RA, Mayer JE, Castaneda AR: Mitral valve replacement in the first year of life. J Thorac Cardiovasc Surg 1990;100:762-8
  8. Zweng TN, Bluett MK, Mosca R, Callow LB, Bove EL: Mitral valve replacement in the first 5 years of life. Ann Thorac Surg 1989;47:720-4
  9. Lewis DA, Tweddell JS: Valve repair and replacement in children. Curr Opin Cardiol 1997;12:63-9
  10. Takahashi T, Morishita Y, Ishikawa S, Ohtaki A, Sato Y, Suzuki M: Valve replacement for children: report of two cases.J Pediatr Surg 1995;30:713 Crawford FA, Selby JH Jr, Joransen JA: Mitral valve replacement with a porcine heterograft in an infant. J Thorac Cardiovasc Surg 1978;75:705-8
  11. Bradley LM, Midgley FM, Watson DC, Getson PR, Scott LP III: Anticoagulation in children with mechanical prosthetic cardiac valve. Am J Cardiol 1985;56:533-5
  12. Schaffer MS, Clarke DR, Campbell DN, Madigan CK, Wiggins JW, Wolfe RR: The St. Jude Medical cardiac valve in infants and children: role of anticoagulant therapy. J Am Coll Cardiol 1987;9:235-9